NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hillstar Bio

Hillstar Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://hillstarbio.com/

Last Round

Series A

Mar 25, 2025

Total Funding Raised

$67M

Company Overview

Hillstar Bio is a biotechnology company that develops next-generation precision immunology therapies for autoimmune diseases by selectively targeting and depleting pathogenic immune cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision immunologybiotechnologyautoimmune diseaseantibody engineeringaxial spondyloarthritisdrug discoveryimmunotherapybiologicsprecision medicinetargeted therapyimmune system resetclinical-stage biotechdrug developmentnext-gen immunologyimmune cell depletion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hillstar Bio Comparables

Compare Hillstar Bio with similar companies based on industry and business-model similarity.

Hillstar Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Santa Ana Bio
82%
Seismic
74%
AbbVie
68%

Hillstar Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 25, 2025

Hillstar Bio Investors

Notable investors and investment history

Hillstar Bio investors
InvestorRounds
Droia VenturesSeries A
Frazier Life SciencesSeries A
Novo HoldingsSeries A
LifeArc VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 24, 2025

    Grew 28% QoQ, from 18 to 23 employees.

  • May 28, 2025

    Maude Tessier appointed as new Chief Operating Officer.

Hillstar Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hillstar Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hillstar Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range19
Year Founded2023
Last FundingMar 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.